Recent News

• 02 December 2025   Press Release

  Peapod Bio Inc. and Enamine Ltd. Announce Strategic Collaboration

  CHICAGO, Peapod Bio Inc., a leader in innovative assay development and high-throughput screening (HTS) solutions, today announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries. This partnership enables Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s world-class compound collections nearing five million compounds, accelerating hit discovery.

• 21 October 2025   Press Release

  Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral

  Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine’s chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of pre-clinical candidate ASAP-0017445. The candidate is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics.

• 23 September 2025   Press Release

  Enamine joins forces with the ICR to expand fragment-based drug discovery with fluorinated compound libraries

  Enamine Ltd., a leading global provider of screening compounds, chemical building blocks, and drug discovery services, and The Institute of Cancer Research, London, have announced a new research collaboration aimed at broadening the tools available for Fragment-based Drug Discovery (FBDD).